Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin + Acalabrutinib in R/R DLBCL and CLL
NCT04502394Phase 2Unknown
- Sponsor
- Kartos Therapeutics
- Start
- Feb 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of navtemadlin in diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL) (2 cohorts), sponsored by Kartos Therapeutics. Primary endpoints: Maximum Tolerated Dose / Maximum Administered Dose / Recommended Phase 2 Dose at 56 days, Complete Response at 1 year and 1 more. Status: unknown.
02
Drugs
navtemadlin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04502394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04502394.